Capeta Nova 500mg Tablet is a potent oral chemotherapy agent containing Capecitabine, specifically engineered for targeted anti-cancer therapy with minimal systemic toxicity. As a prodrug of 5-Fluorouracil (5-FU), Capecitabine selectively activates within tumor tissues, disrupting DNA synthesis in cancerous cells, consequently inducing apoptosis and inhibiting cancer progression. This tablet is primarily indicated for the treatment of colorectal, metastatic breast (resistant to paclitaxel and anthracyclines), and advanced/metastatic gastric cancers, either as monotherapy or in combination chemotherapy regimens. The 500 mg formulation facilitates flexible dosing based on body surface area (1250 mg/m² twice daily), administered orally post meals to optimize absorption and minimize gastrointestinal side effects. The product ensures convenience, reducing hospitalization needs and demonstrating a superior safety profile due to tumor-selective activation, making it essential for oncologists managing advanced solid tumors. Its packaging in boxes of 120 tablets enables extended treatment cycles, while stringent storage recommendations protect efficacy and stability. This oral anticancer therapy demands careful dose adjustments in renal impairments and caution in pregnant or breastfeeding patients, underscoring its use under strict medical supervision.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Capecitabine 500 mg per tablet |
| Mechanism of Action | Prodrug of 5-Fluorouracil, selectively activated in tumor cells inhibiting DNA synthesis |
| Indications | Colorectal, metastatic breast, and advanced/metastatic gastric cancers |
| Dosage Form | Oral tablet |
| Dosage Regimen | 1250 mg/m² twice daily for 14 days followed by 7 days rest in 21-day cycles |
| Packaging | Box of 120 tablets (500 mg each) |
| Storage Conditions | Store below 25°C, dry and protected from light and moisture |
| Therapeutic Category | Oncology / Antimetabolite Chemotherapy |
| Safety Profile | Selective tumor activation reduces systemic toxicity |
| Administration Guidance | Swallow tablets with water within 30 minutes after a meal |
| Attributes | Description |
|---|---|
| Generic Name | Capecitabine |
| Brand Name | Capeta Nova |
| Strength | 500 mg per tablet |
| Tablet Count | 120 tablets per box |
| Chemical Class | Oral fluoropyrimidine carbamate |
| Route of Administration | Oral |
| Pharmacological Action | Antimetabolite chemotherapy agent |
| Contraindications | Pregnancy, breastfeeding |
| Common Side Effects | Hand-foot syndrome, diarrhea, nausea, fatigue |
| Dose Adjustment | Required in renal impairment |
| Manufacturer | Nova |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Capeta Nova contains Capecitabine, a prodrug enzymatically converted to 5-FU selectively within tumor tissues, which reduces systemic exposure and lowers toxicity compared to direct intravenous 5-FU.
Yes, Capeta Nova can be used alone or combined with other chemotherapeutic agents for enhanced efficacy against solid tumors like colorectal and gastric cancers.
The tablets must be stored below 25°C in a dry place, protected from light and moisture to preserve stability and effectiveness.
Yes, renal impairment requires careful dose modification to avoid increased toxicity while maintaining optimal therapeutic effect.
Capeta Nova is contraindicated during pregnancy and breastfeeding due to potential harm to the fetus and infant; it should only be used under strict medical supervision.
Typically, 1250 mg/m² is taken orally twice daily for 14 days followed by a 7-day rest, forming a 21-day treatment cycle, always under oncologist supervision.
Country Of Origin: India
Product Name: Capeta Nova 500mg Tablet
Generic Name: Capecitabine 500 mg
Manufacturer: Nova (Capeta Nova brand)
Therapeutic Category:Oncology / Antimetabolite Chemotherapy
Product Description:
Capeta Nova 500mg contains Capecitabine, an oral fluoropyrimidine carbamate that acts as a prodrug of 5-Fluorouracil (5-FU).
It is specifically designed to be activated in tumor tissues, minimizing systemic toxicity and enhancing anticancer activity.
Capecitabine interferes with DNA synthesis in rapidly dividing cancer cells, leading to their death.
Indications:
• Colorectal Cancer (adjuvant and metastatic)
• Breast Cancer (metastatic, resistant to paclitaxel/anthracycline regimens)
• Gastric Cancer (advanced/metastatic)
• Used as monotherapy or in combination regimens with other chemotherapeutic agents
Mechanism of Action:
• Capecitabine is converted enzymatically into 5-FU within tumor cells.
• 5-FU inhibits thymidylate synthase, preventing DNA replication and cell division.
• Selective activation in tumor tissue reduces systemic toxicity compared to direct 5-FU therapy.
Dosage & Administration:
• Typical dose: 1250 mg/m² orally twice daily for 14 days, followed by 7 days rest (21-day cycle).
• Dose adjustments are based on toxicity and patient condition.
• Tablets should be swallowed with water within 30 minutes after a meal.
(Only to be prescribed and supervised by an oncologist.)
Key Benefits:
• Oral chemotherapy – no hospitalization required.
• Tumor-targeted activation for better safety profile.
• Effective in multiple solid tumors including breast, colon, and gastric cancers.
Packaging:
• Box of 120 tablets (500 mg each)
• Also available in 150 mg strength (varies by brand/market)
Storage:
• Store below 25°C, in a dry place.
• Protect from light and moisture.
Important Notes:
• For oncology use only.
• Side effects may include hand-foot syndrome, diarrhea, nausea, fatigue.
• Dose modification required in renal impairment.
• Contraindicated in pregnancy and breastfeeding.
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
